ArticleDermatologic therapy2022

Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.

Giacomo Caldarola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.